Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
J Rheumatol
; 48(5): 693-697, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33191289
ABSTRACT
OBJECTIVE:
Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).METHODS:
Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included.RESULTS:
In total, 150 patients initiated monotherapy (apremilast n = 34; MTX n = 15; bDMARD n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators.CONCLUSION:
Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Psoriatic
/
Antirheumatic Agents
/
Spondylarthritis
Limits:
Humans
Language:
En
Journal:
J Rheumatol
Year:
2021
Document type:
Article